Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy

S. Fröjdö, L. Sjölind, M. Parkkonen, V. P. Mäkinen, R. Kilpikari, K. Pettersson-Fernholm, C. Forsblom, J. Fagerudd, C. Tikellis, M. E. Cooper, M. Wessman, P. H. Groop

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Aims/hypothesis: Substantial evidence exists for the involvement of the renin-angiotensin system (RAS) in diabetic nephropathy. Angiotensin I converting enzyme 2 (ACE2), a new component of the RAS, has been implicated in kidney disease, hypertension and cardiac function. Based on this, the aim of the present study was to evaluate whether variations in ACE2 are associated with diabetic nephropathy. Materials and methods: We used a cross-sectional, case-control study design to investigate 823 Finnish type 1 diabetic patients (365 with and 458 without nephropathy). Five single-nucleotide polymorphisms (SNPs) were genotyped using TaqMan technology. Haplotypes were estimated using PHASE software, and haplotype frequency differences were analysed using a χ 2-test-based tool. Results: None of the ACE2 polymorphisms was associated with diabetic nephropathy, and this finding was supported by the haplotype analysis. The ACE2 polymorphisms were not associated with blood pressure, BMI or HbA1c. Conclusions/interpretation: In Finnish type 1 diabetic patients, ACE2 polymorphisms are not associated with diabetic nephropathy or any studied risk factor for this complication. Further studies are necessary to assess a minor effect of ACE2.

Original languageEnglish
Pages (from-to)2278-2281
Number of pages4
Issue number11
Publication statusPublished or Issued - Nov 2005
Externally publishedYes


  • ACE2
  • Diabetic nephropathy
  • Haplotype
  • SNP
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this